Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GH Guardant Health	$58.57 +6.3%	$48.76	$20.14 ▼ $58.62	$6.87B	1.43	3.03 million shs	3.05 million shs
HIMS Hims & Hers Health	$48.34 +0.8%	$53.28	$13.47 ▼ $72.98	$10.73B	2.08	37.54 million shs	19.19 million shs
NTRA Natera	$157.70 -1.3%	$155.33	$110.57 ▼ $183.00	$21.93B	1.76	1.74 million shs	1.20 million shs
RDNT RadNet	$68.40 +7.5%	$56.98	$45.00 ▼ $93.65	$4.89B	1.43	932,404 shs	1.95 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GH Guardant Health	+0.55%	+19.34%	+9.65%	+35.31%	+80.83%
HIMS Hims & Hers Health	-4.10%	-13.67%	-0.06%	-22.55%	+199.81%
NTRA Natera	+1.76%	+14.05%	-0.39%	+5.60%	+38.66%
RDNT RadNet	+2.58%	+14.68%	+14.64%	+5.40%	+3.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GH Guardant Health	2.7576 of 5 stars	1.5	1.0	4.4	2.2	2.5	0.6
HIMS Hims & Hers Health	2.7264 of 5 stars	2.0	3.0	0.0	2.9	3.3	1.9
NTRA Natera	3.6972 of 5 stars	3.5	5.0	0.0	3.3	2.5	0.6
RDNT RadNet	3.2925 of 5 stars	1.7	2.0	4.6	3.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GH Guardant Health	3.06	Buy	$57.50	-1.83% Downside
HIMS Hims & Hers Health	1.92	Reduce	$39.83	-17.60% Downside
NTRA Natera	3.06	Buy	$193.87	22.93% Upside
RDNT RadNet	3.43	Buy	$71.60	4.68% Upside

Current Analyst Ratings Breakdown

Latest NTRA, HIMS, GH, and RDNT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	RDNT RadNet	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$66.00 ➝ $75.00
8/11/2025	RDNT RadNet	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Overweight
8/11/2025	NTRA Natera	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$210.00 ➝ $220.00
8/10/2025	NTRA Natera	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$195.00
8/8/2025	NTRA Natera	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	NTRA Natera	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$190.00 ➝ $210.00
8/8/2025	NTRA Natera	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$251.00 ➝ $255.00
8/5/2025	HIMS Hims & Hers Health	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/31/2025	GH Guardant Health	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$57.00 ➝ $60.00
7/31/2025	GH Guardant Health	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$59.00 ➝ $61.00
7/28/2025	NTRA Natera	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$170.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GH Guardant Health	$828.85M	8.81	N/A	N/A	($2.45) per share	-23.91
HIMS Hims & Hers Health	$1.48B	7.33	$0.34 per share	141.92	$2.51 per share	19.26
NTRA Natera	$1.70B	12.76	N/A	N/A	$9.08 per share	17.37
RDNT RadNet	$1.83B	2.80	$3.84 per share	17.80	$15.31 per share	4.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GH Guardant Health	-$436.37M	-$3.35	N/A	N/A	N/A	-49.93%	N/A	-28.95%	N/A
HIMS Hims & Hers Health	$126.04M	$0.80	60.43	92.96	3.16	9.63%	26.26%	13.06%	N/A
NTRA Natera	-$190.43M	-$1.91	N/A	N/A	N/A	-12.89%	-22.22%	-15.03%	N/A
RDNT RadNet	$2.79M	-$0.43	N/A	129.05	N/A	-0.78%	2.44%	0.84%	N/A

Latest NTRA, HIMS, GH, and RDNT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2025	Q2 2025	RDNT RadNet	$0.17	$0.31	+$0.14	$0.43	$488.06 million	$498.23 million
8/7/2025	Q2 2025	NTRA Natera	-$0.60	-$0.74	-$0.14	-$0.74	$476.84 million	$546.60 million
8/4/2025	Q2 2025	HIMS Hims & Hers Health	$0.18	$0.17	-$0.01	$0.17	$550.06 million	$544.83 million
7/30/2025	Q2 2025	GH Guardant Health	-$0.52	-$0.44	+$0.08	-$0.80	$211.19 million	$232.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
RDNT RadNet	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GH Guardant Health	N/A	3.71	3.35
HIMS Hims & Hers Health	1.72	4.98	4.46
NTRA Natera	N/A	3.72	3.74
RDNT RadNet	0.91	2.00	2.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GH Guardant Health	92.60%
HIMS Hims & Hers Health	63.52%
NTRA Natera	99.90%
RDNT RadNet	77.90%

Insider Ownership

Company	Insider Ownership
GH Guardant Health	6.10%
HIMS Hims & Hers Health	17.71%
NTRA Natera	5.63%
RDNT RadNet	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GH Guardant Health	2,021	124.71 million	117.10 million	Not Optionable
HIMS Hims & Hers Health	1,637	223.83 million	184.19 million	Optionable
NTRA Natera	4,434	137.25 million	128.86 million	Optionable
RDNT RadNet	11,021	75.03 million	70.83 million	Optionable

HIMS, NTRA, GH, and RDNT Headlines

Recent News About These Companies

RadNet, Inc. (NASDAQ:RDNT) Q2 2025 Earnings Call Transcript

August 12 at 5:42 PM | msn.com

RadNet (NASDAQ:RDNT) Shares Gap Up - Here's Why

August 12 at 1:54 PM | marketbeat.com

RadNet (NASDAQ:RDNT) Announces Earnings Results, Beats Expectations By $0.14 EPS

August 12 at 9:16 AM | marketbeat.com

Natixis Advisors LLC Trims Stock Holdings in RadNet, Inc. (NASDAQ:RDNT)

August 12 at 3:35 AM | marketbeat.com

RadNet (NASDAQ:RDNT) & Ontrak (NASDAQ:OTRK) Head to Head Analysis

August 12 at 2:51 AM | americanbankingnews.com

RadNet: Q2 Earnings Snapshot

August 12 at 2:26 AM | timesunion.comT

RadNet rises 16.8%

August 12 at 2:26 AM | msn.com

RadNet Posts Better-Than-Expected Earnings, Joins Tegna, MeridianLink, Lithium Argentina And Other Big Stocks Moving Higher On Monday

August 12 at 2:26 AM | benzinga.com

RadNet, Inc. (RDNT) Q2 2025 Earnings Call Transcript

August 11 at 1:05 PM | seekingalpha.com

RadNet (RDNT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

August 11 at 10:31 AM | zacks.com

Zions Bancorporation National Association UT Makes New Investment in RadNet, Inc. (NASDAQ:RDNT)

August 11 at 4:52 AM | marketbeat.com

RadNet, Inc. Reports 8.4% Revenue Growth and Record Adjusted EBITDA in Q2 2025

August 10 at 4:45 PM | quiverquant.comQ

RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges

August 10 at 4:00 PM | globenewswire.com

RadNet, Inc. (NASDAQ:RDNT) Shares Acquired by Global Alpha Capital Management Ltd.

August 10 at 7:55 AM | marketbeat.com

Earnings To Watch: RadNet Inc (RDNT) Reports Q2 2025 Result

August 10 at 2:39 AM | finance.yahoo.com

RadNet (RDNT) Reports Q2: Everything You Need To Know Ahead Of Earnings

August 9, 2025 | msn.com

RadNet, Inc. (NASDAQ:RDNT) Given Average Rating of "Strong Buy" by Analysts

August 9, 2025 | americanbankingnews.com

RadNet (RDNT) Expected to Announce Quarterly Earnings on Sunday

August 9, 2025 | americanbankingnews.com

DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive™

August 7, 2025 | finance.yahoo.com

Wall Street's Insights Into Key Metrics Ahead of RadNet (RDNT) Q2 Earnings

August 6, 2025 | zacks.com

RadNet, Inc. (NASDAQ:RDNT) Shares Bought by Scotia Capital Inc.

August 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HIMS, NTRA, GH, and RDNT Company Descriptions

Guardant Health NASDAQ:GH

$58.57 +3.47 (+6.30%)

Closing price 04:00 PM Eastern

Extended Trading

$57.88 -0.69 (-1.18%)

As of 07:44 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Hims & Hers Health NYSE:HIMS

$48.34 +0.38 (+0.79%)

Closing price 03:59 PM Eastern

Extended Trading

$48.44 +0.10 (+0.21%)

As of 07:59 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Natera NASDAQ:NTRA

$157.70 -2.11 (-1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$156.56 -1.13 (-0.72%)

As of 07:45 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

RadNet NASDAQ:RDNT

$68.40 +4.80 (+7.54%)

Closing price 03:59 PM Eastern

Extended Trading

$68.48 +0.08 (+0.12%)

As of 07:54 PM Eastern

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time